On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in development and commercial milestones, plus tiered sales royalties. While the therapeutic target remains undisclosed, the deal pairs a micro-cap discovery engine with a megacap pharmaceutical titan. A look at their latest financial profiles reveals a contrast in scale, momentum, and operational risk.
Comparing the Financials: A High-Growth Megacap vs. an Emerging Micro-Cap
Eli Lilly and Company (NYSE:LLY) is comfortably outperforming in sheer financial scale and top-line expansion, operating as one of healthcare’s strongest commercial engines. In Q2 2026, Lilly generated $23 billion in revenue, up 48% year-over-year, propelled by demand for its GLP-1 treatments, Mounjaro and Zepbound. Non-GAAP earnings reached $8.38 per share, easily beating estimates and allowing Lilly to raise its full-year 2026 revenue guidance to $85.0–$87.0 billion. Despite absorbable headwinds, such as $3.03 per share in business development charges, Lilly’s $7.09 billion net quarterly income underscores its dominance.
OmniAb, Inc. (NASDAQ:OABI) operates on a fundamentally different, asset-light royalty model. In Q2 2026, OmniAb reported revenue of $13.4 million, a sharp increase from $3.9 million in Q2 2025, driven by milestone receipts, service revenue, and instrument sales. Operating expenses held flat at $20.1 million, helping narrow its quarterly net loss to $5.9 million (from $15.9 million a year prior). Management raised full-year 2026 revenue guidance to $32–$36 million and expects to end the year with $37–$41 million in cash. While OmniAb is scaling rapidly relative to its baseline, Lilly is the far superior financial performer in profitability, cash flow generation, and commercial maturity.
Bull and Bear Cases
For Eli Lilly, the bull case rests on its position in metabolic disease, oncology, and immunology, paired with a massive clinical pipeline. Raising full-year guidance confirms that high demand continues to overcome price erosion. The bear case centers on valuation expectations, potential Medicare price negotiations, and escalating competition in the obesity market.
For OmniAb, the bull case hinges on its high-margin licensing model. With 110 active partners and 425 active programs, new deals like Lilly’s provide non-dilutive capital and downstream royalty potential without requiring costly late-stage clinical trials. The bear case is rooted in its cash burn and micro-cap volatility; until downstream programs enter late-stage commercialization, lumpier milestone revenues leave the company unprofitable and exposed to partner pipeline cancellations.
Insider Monkey’s Hedge Fund Data Analysis
Institutional interest reflects the structural divide between the two stocks. Institutional interest in Eli Lilly remains high, with Insider Monkey’s database recording 132 hedge fund holdings in Q1 2026 (down slightly from 137 in Q4 2025). Top holders include Ken Fisher’s Fisher Asset Management ($6.07 billion position, up 5%) and Ken Griffin’s Citadel Investment Group.
Meanwhile, OmniAb holds niche institutional backing, tracked in 20 hedge funds in Q1 2026 (down from 21 in Q4 2025). Its major holders include David Salanic’s Whitefort Capital ($25.2 million value, representing 6.21% of its portfolio despite a 28% trimmed stake) and Eric Bannasch’s Cadian Capital ($10.4 million value, up 2%).
Conclusion: What Investors Should Watch Next
The Lilly-OmniAb partnership illustrates two distinct ways to play healthcare innovation: buying the established commercial giant or speculating on the tech enabler. Moving forward, Eli Lilly and Company (NYSE:LLY) investors should monitor execution on its raised revenue guidance, supply chain expansions for Mounjaro/Zepbound, and Phase 3 trial updates for next-generation assets like retatrutide. For OmniAb, Inc. (NASDAQ:OABI), investors should keep a close eye on the transition of its 34 clinical-stage partner programs toward pivotal trials, full-year cash burn management against its $37–$41 million year-end target, and further disclosures regarding the initial target validation under the new Lilly alliance.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center